BioSpace News Archive

Can-Fite BioPharma Ltd. reported that the International Journal of Molecular Sciences published a scientific review by independent scientists summarizing >50 publications from scientists all over the world stating that piclidenoson and namodenoson have a positive effect on heart diseases.

Aldeyra Therapeutics, Inc. today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference.

Alentis Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted lixudebart (ALE.F02) Orphan Drug designation for the treatment of Idiopathic Pulmonary Fibrosis (IPF).

Surmodics, Inc. today announced that it has entered into a definitive agreement to be acquired by GTCR, a leading private equity firm with a long track record of investment expertise across healthcare and healthcare technology.

Ocugen, Inc. today announced that the Company will present at the 2024 BIO International Convention taking place in San Diego, CA from June 3 – 6, 2024.

Biohaven Ltd. announced the first patient has been dosed in a first-in-human Phase 1/2 study of BHV-1510, a highly differentiated Trophoblast Cell Surface Antigen-2 (Trop-2) directed Antibody Drug Conjugate (ADC), and the lead ADC program to advance into clinical trials in Biohaven’s growing oncology pipeline.

CareDx, Inc. today announced that the Company will participate in two upcoming investor conferences.

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, announced initial data from the Phase 1 MINOTAUR study evaluating lunresertib (RP-6306) in combination with FOLFIRI for the treatment of advanced solid tumors has been selected for a poster presentation at the European Society of Medical Oncology (ESMO) Gastrointestinal (GI) Cancers Congress 2024, being held June 26-29.

Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its fiscal 2024 second quarter results for the period ended March 31, 2024.

FDA Grants Priority Review to Merck’s Application for KEYTRUDA ® (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma.